Siluria Technologies, the California-based methane conversion company, has landed $20 million in the form of a Series B investment led by the Wellcome Trust, a UK-based foundation. Other investors include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
You are browsing the archive for Altitude Life Science Ventures - peHUB.
Siluria Technologies, a San Francisco-based developer of methane-based alternatives for producing fuels and chemicals normally derived from oil, has raised $20 million in new capital. The Series B round was led by UK-based Wellcome Trust, with participation from Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
KYTHERA Biopharmaceuticals Inc., a company developing products in aesthetic medicine, has closed on $37.4 million in Series D financing. KYTHERA’s investors include Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, JAFCO, Partner Funds management, INVUS Financial Advisors, BBT Capital Management, and Altitude Life Science Ventures. Also joining the syndicate were Foley Ventures and Latham and Watkins. KYTHERA has now raised more than $108 million to date.
Constellation Pharmaceuticals has raised $15 million in an extension to its Series B round, the company announced Monday. Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures – all existing shareholders – participated in the round. The latest infusion will help Constellation move its products toward clinical development. The company develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders and other diseases.
Guilford, Conn.-based online advertising start-up uKnow has raised roughly half of a planned $1 million funding round, according to a filing with the SEC. Angel investor Geoff Judge, who is also a partner with iNovia Capital, is listed among the company’s directors. Pittsburgh-based Neograft has raised $3 million according to an SEC filing. Neograft develops [...]